DoseMeRx vs PrecisePK (2026)
Two Bayesian dosing platforms with different strengths. DoseMeRx shows the pharmacist how well the model fits this patient's measured concentrations alongside the dose, which tells you when to distrust the answer. It holds HITRUST certification and states exactly where patient data is stored. PrecisePK leads on published assurance terms. Its business associate agreement is published in full at an open URL, and it names SOC 2 Type 2 and ISO/IEC 27001 certification with copies on request. It also walks through its computation step by step rather than calling it proprietary. Its strongest published result is an independent 2018 comparison in 19 critically ill patients, which is small and should be read with that limit attached.
- The interface shows how well the model fits this patient's measured concentrations alongside the recommended dose, so a pharmacist can see when the model is struggling.
- Residency is stated exactly: United States data in a Microsoft Azure facility in Illinois, and European data in EU data centers.
- Most of its published studies are written by hospital clinicians, including a 2023 study associating its vancomycin dosing with lower acute kidney injury than first order calculation in patients also receiving piperacillin tazobactam.
- The business associate agreement is published in full at an open URL, so every customer signs the same terms.
- It names SOC 2 Type 2 and ISO/IEC 27001:2022 certification and offers copies on request.
- The technology page walks through the computation in sequence, from population model through Bayesian updating.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. DoseMeRx and PrecisePK are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | DoseMeRx | PrecisePK |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Medication Safety & Prescribing |
| Founded | 2012 | Not recorded |
| Headquarters | Houston, Texas, United States | San Diego, California, United States |
| Website | doseme-rx.com | precisepk.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
DoseMeRx is a Bayesian precision dosing platform for high risk medications, computing an individualized regimen from named, clinically validated population pharmacokinetic models, patient characteristics, measured drug concentrations and, where available, genotype.
Source: AI Health Index, September 2026
PrecisePK is Bayesian therapeutic drug monitoring software from Healthware, Inc. in San Diego, with a clinical lineage going back more than thirty years. It began as T.D.M.S. 2000, developed by Philip Anderson, a doctor of pharmacy, with pharmacokinetic consultants, and programmed by Anjum Gupta, a computer scientist, both professors at the University of California, San Diego, and beta tested by the Applied Pharmacokinetics Service at UCSD Medical Center and Rady Children's Hospital.
Source: AI Health Index, September 2026
Questions buyers ask
How do DoseMeRx and PrecisePK work with the EHR?
The most consequential integration runs through another vendor's product: in October 2025 Inovalon announced a collaboration bringing DoseMeRx dosing into its pharmacy surveillance workflows, so the software reaches clinicians inside a surveillance platform as well as directly.
PrecisePK's own material says that when integrated with an EHR the software retrieves patient information from it, and treats integration as a purchasing consideration alongside clinical surveillance tools and reporting compliance. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
How are DoseMeRx and PrecisePK priced and sold?
In DoseMeRx's case, a fourteen day free trial covers the full platform including all drug packages, so an evaluating pharmacy is not restricted to a limited module set. A partnership with the American Society of Health System Pharmacists aimed at small and rural hospitals bundles that society's competency management subscription with unlimited use of the platform for up to ten users at a single site, stated to be open to non members.
For PrecisePK, the site offers a sixty day free trial of the software prominently and repeatedly, a concrete commercial term that lets a pharmacy department test accuracy against its own patients before committing. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
Which settings and specialties do DoseMeRx and PrecisePK cover?
With DoseMeRx, the function itself stays narrow: high risk medications with therapeutic drug monitoring.
In PrecisePK's case, the product supports therapeutic drug monitoring across the drug classes where measured concentrations guide dosing, with vancomycin dominating current practice and the aminoglycosides and other narrow therapeutic index agents alongside it, and the company states use in all types of patients. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
What evidence is published for DoseMeRx and PrecisePK?
For DoseMeRx, an independent 2018 comparison in Pharmacotherapy included DoseMe among five programs.
Turner and colleagues at Pacific University School of Pharmacy, publishing in Pharmacotherapy in 2018, compared five Bayesian dose optimizing programs and two first order equations for estimating vancomycin area under the curve in critically ill patients, and found PrecisePK the least biased of the group at a median of 5.1 percent. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Neither product holds a device clearance and neither claims one, the usual position for therapeutic drug monitoring software, so the computed dose has not been reviewed by a regulator. Neither publishes performance compared across age, sex, renal function band or body size, and dosing models are known to perform differently across those groups. PrecisePK's independent evidence covers 19 patients. DoseMeRx's studies are mostly written by hospital clinicians rather than by the company.